340B Legislative Reforms: Where Do We Go From Here?
Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.
You may also be interested in...
340B Hospitals Could See Audits On Use Of Drug Price Savings Under Biden Administration Proposal
Legislation would be needed and will be complicated to develop. While the effectiveness of existing audits has been question by a federal government watchdog, the proposal in Biden’s budget document suggests the administration has some sympathy with drug sponsors’ position in the ongoing fight over the 340B drug discount program.
Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
340B Reform: US House Bills Mark The End Of The Beginning
Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.